Antibiotic-resistant bacteria are a global health issue necessitating the development of new effective therapeutics. Proline-rich antimicrobial peptides (PrAMPs), which include oncocins, are an extensively studied class of AMPs that counteract bacterial infection at submicromolar concentrations. Oncocins enter and kill bacteria by inhibiting certain targets rather than by acting through membrane lysis. Although they have recently been reported to bind DnaK and the bacterial ribosome, their mode of inhibition has remained elusive. Here we report the crystal structure of the oncocin derivative Onc112 bound to the Thermus thermophilus 70S ribosome. Strikingly, this 19-residue proline-rich peptide manifests the features of several known classes of ribosome inhibitors by simultaneously blocking the peptidyl transferase center and the peptide-exit tunnel of the ribosome. This high-resolution structure thus reveals the mechanism by which oncocins inhibit protein synthesis, providing an opportunity for structure-based design of new-generation therapeutics.
a r t i c l e s Throughout the course of evolution, the innate immune system in plants and animals has developed efficient ways to counter infections. One of the lines of defense is through the synthesis of antimicrobial peptides (AMPs) that kill bacterial and fungal pathogens [1] [2] [3] . These AMPs are an effective weapon against the ability of microorganisms to develop resistance 4 . Most AMPs are small peptides of 15-70 amino acid residues generated from post-translational processing of larger precursors, whose synthesis is induced through the Toll and Toll-like receptors 4, 5 . Although AMPs are extremely diverse, they can be categorized into several groups on the basis of their structures or sequences as α-helical, cysteine-rich, glycine-rich and proline-rich peptides 1 .
The PrAMPs, expressed in mammals and insects, have attracted particular attention because of their wide distribution and unique mechanism of killing bacteria without cell-membrane disruption 6 . The PrAMPs oncocin, apidaecin, drosocin and pyrrhocoricin interact with the substrate-binding domain of the chaperone DnaK with dissociation constants in the micromolar range, thus resulting in protein misfolding and aggregation, and subsequent bacterial death [7] [8] [9] [10] [11] . This mechanism is bacteria specific because PrAMPs are only slightly toxic toward mammalian cells, owing to their inability to penetrate the mammalian cell membrane 12 . Structural studies of bacterial DnaK complexes with PrAMPs have revealed two modes for PrAMP binding to the conventional binding cleft of DnaK 13, 14 , indicating that DnaK is rather promiscuous in peptide binding.
Recent biochemical data have demonstrated that an apidaecin derivative, Api88, and its truncated mutants are equally efficient in entering Escherichia coli cells and binding to DnaK. However, only the full-length Api88 is functional 15 . This, combined with the susceptibility of a DnaK-null mutant to PrAMPs, suggests that DnaK is not the main target for this group of peptides 16 . Cross-linking, cell-free translation and binding assays have shown that apidaecin derivatives (Api88 and Api137) and oncocin derivatives (Onc72 and Onc112) inhibit protein synthesis by binding the 70S ribosome with dissociation constants in the nanomolar range 16 . Remarkably, Onc112 binds to the 70S ribosome approximately 50-fold more strongly than it does to DnaK 16 , thus making the ribosome the preferred target.
To gain insights into the mode of its interaction, we have determined the 2.9-Å-resolution crystal structure of Onc112 bound to the T. thermophilus 70S ribosome in complex with mRNA and a tRNA fMet in the peptidyl (P) site (Online Methods and Table 1 ). Remarkably, unlike most known antibiotics, a single Onc112 molecule interacts with not just one but three adjacent functional sites of the ribosome. Its N terminus binds near the peptidyl transferase center (PTC) of the 50S subunit, where it interferes with the aminoacyl (A)-site tRNA and the peptidyl-tRNA in the P site. The rest of Onc112 binds inside the peptide-exit tunnel of the 50S subunit and blocks it completely ( Fig. 1) .
Our study provides insights into the mechanism by which PrAMPs inhibit translation and builds a foundation for further structure-based design of a new generation of antimicrobial therapeutics, which may be more effective against the development of bacterial drug resistance. In addition, the visualization of a peptide in the 50S-subunit exit tunnel at high resolution sheds light on the function of the tunnel during translation.
RESULTS
We determined the structure of the 70S ribosome complex with Onc112 by molecular replacement, with a high-resolution model of the 70S ribosome with its ligands removed 17 as a search model (Online Methods). Clear unbiased electron density for the mRNA, P-site tRNA fMet and Onc112 inside the peptide tunnel of the 50S subunit with its N terminus near the acceptor stem of the tRNA fMet appeared after calculation of the difference Fourier map from initially phased diffraction data ( Fig. 1a,b and Supplementary Fig. 1 ).
Throughout the text, we use E. coli nucleotide numbering, with the T. thermophilus numbers following in parentheses.
Interactions of the Onc112 N terminus with the ribosome
The universally conserved PTC of the ribosome, which is made exclusively of RNA, catalyzes peptide-bond formation between the incoming aminoacyl-tRNA and the peptidyl-tRNA, both of which must be properly aligned in the A and P sites, respectively 17 . Although most antibiotics target only certain parts of the PTC or the peptide-exit tunnel, Onc112 overlaps with all of those binding sites located in the 50S exit tunnel (Figs. 1a,b, 2c and 3c) . Surprisingly, the orientation of Onc112 inside the peptide tunnel is opposite to that of a natural nascent peptide chain, for which incoming amino acids are added C terminally in the PTC. The N terminus of Onc112 (residues 1 to 5) follows the path of the CCA end of the acceptor stem and of the aminoacyl moiety of an A-site tRNA ( Fig. 2a and Supplementary Fig. 2a ). The first three residues of Onc112 form multiple interactions with the 23S rRNA. For instance, the main chain peptide backbone of Val1 and the side chain of Asp2 form hydrogen-bonding interactions with nucleotides C2573 (2584) and G2553 (2564), respectively ( Fig. 1c and Supplementary Fig. 3a) . The latter nucleotide is part of the A loop of the 23S rRNA, and it normally forms a Watson-Crick base pair with C75 of the A-site tRNA 17 . This interaction is partially replaced by the γ-carboxyl group of the Asp2 side chain, which superposes with the Watson-Crick edge of nucleotide C75 of an accommodated tRNA in the A site 17 (Supplementary Fig. 3b ). The side chain of Lys3 is fully extended, and it forms nonspecific electrostatic interactions with 23S rRNA (Fig. 1c) . These interactions ensure that the binding of Onc112 to the ribosome and of the tRNA to the A site of the 50S subunit are mutually exclusive. Moreover, the binding of Onc112 reorients nucleotide U2585 (2596) so that it would collide with the amino acid moiety attached to the peptidyl-tRNA in the P site ( Supplementary Fig. 2b) . By interfering directly with the binding of the CCA end of the aminoacyl-tRNA in the PTC and indirectly with 
Interactions of Onc112 within the PTC
The middle part of Onc112 (residues 6 to 8) occupies the A-site cleft in the PTC, which forms one side of the peptide-exit-tunnel wall, where the aminoacyl moiety of an A-site tRNA would normally bind (Fig. 1d) . The Tyr6 residue, located right after a consecutive pair of prolines, is rotationally confined such that its phenyl ring forms a stacking interaction with the nucleotide base of C2452 (2463), in a manner analogous to binding of the phenyl moiety of a Phe-tRNA Phe in the A site 17 (Fig. 2b) , while its hydroxyl group forms a hydrogen bond with a water molecule (Supplementary Fig. 4b ). This binding mode is also similar to that of the antibiotics chloramphenicol (CAM) and homoharringtonine (HHT) [18] [19] [20] [21] (Fig. 2c) . Like Onc112, CAM also displays broad-spectrum activity in bacteria but does not inhibit eukaryotic translation. However, in contrast to the structure of the CAM complex, nucleotide U2585 (2596) in this Onc112-70S complex is rotated by about 55°, and the base of A2062 (2083) is rotated by about 45° to accommodate Pro5 and Pro8 of the peptide, respectively (Fig. 3a,b) . In addition, the interactions of Onc112 with the A-site cleft in the PTC are further stabilized by the Leu7 side chain, which caps a three-layer stacked unit, and by the N3 and O2 of U2506 (2517), which interact with the main chain of residues Tyr6 and Leu7 ( Fig. 1d and Supplementary Fig. 4a) . The high conservation of this region of the ribosome suggests that Onc112 will probably inhibit eukaryotic protein synthesis, provided that it passes through the cell membrane.
Interactions of Onc112 in the exit tunnel
In the upper chamber of the peptide-exit tunnel, the nucleotide base of A2062 (2083) adopts a conformation allowing the side chain of Arg11 to form a favorable stacking interaction with its nucleotide base ( Figs. 1e and 3b) . We also observed a similar interaction between Arg9 and C2610 (2621) ( Figs. 1e and 3b) . These extended arginine side chains span about 16 Å across the ribosome peptide-exit tunnel, thereby completely plugging the upper chamber ( Figs. 1e and 3b) . Interestingly, nucleotide A2062 (2083) adopts different conformations when interacting with erythromycin on the stalled ribosome 22, 23 . Its mutation, as well as mutation of C2610 (2621), substantially reduces nascent peptide-dependent and antibiotic-dependent ribosome stalling 24, 25 . The location of Onc112 overlaps with the macrolide antibiotics erythromycin and azithromycin 18 (Fig. 3c) , thus explaining the antimicrobial effects of Onc112, which occupies the binding sites of several classes of antibiotics. Our data explain the previous observation that alanine substitutions of Lys3, Tyr6, Leu7 and Arg11 severely reduce the antimicrobial activity of oncocin 26 and decrease its binding affinity to the 70S ribosome by more than 30-fold 16 . The side chains of these residues are all involved in tight interactions with the 23S rRNA, and their mutation will consequently affect the binding of oncocin to the ribosome. We do not see electron density for the last six amino acid residues of Onc112, a result suggesting that they are flexible and probably not essential for the binding to the ribosome.
DISCUSSION
The crystal structure of the proline-rich peptide Onc112 bound to the 70S ribosome highlights the network of extensive interactions between the peptide and the 23S rRNA. This peptide forms a 34-Å-long plug that blocks access to the A and P sites, the peptidyl transferase center and the peptide-exit tunnel of the 50S ribosomal subunit. The path of the peptide overlaps with the binding sites of multiple classes of antibiotics, thus suggesting that it inhibits the bacterial ribosome through a concerted mode of action. This would probably prevent the transition to the elongation phase of protein synthesis and result in the accumulation of 70S ribosomal particles. The structure presented b c npg a r t i c l e s here sheds light on the mechanism that has evolved in eukaryotic organisms to defeat bacterial resistance to ribosome-targeting compounds. Such peptides, which simultaneously occupy multiple drugbinding sites, limit the probability of the appearance of resistance mutations. Our study builds a platform for structure-based design of the next generation of improved antimicrobial agents.
METHODS
Methods and any associated references are available in the online version of the paper.
ONLINE METHODS

Synthesis of mRNAs, tRNAs and peptides.
The mRNA with a Shine-Dalgarno sequence and an initiation codon in the P site was synthesized by integrated DNA technologies with the sequence 5′ GGC AAG GAG GUA AAA AUG UUC UAA 3′. The fMet-tRNA fMet was prepared as previously described 27 . The oncocin derivative, peptide Onc112, with the sequence VDKPPYLPRPRPPRrIYNr-NH 2 16 , where ′r′ stands for d-arginine, was chemically synthesized by GenScript USA.
Complex formation and crystallization. The T. thermophilus 70S ribosomes were purified, crystallized and cryoprotected as previously described 28 . Essentially, 4 µM ribosomes were incubated with 8 µM mRNA and fMet-tRNA fMet in 50 mM KCl, 5 mM HEPES-KOH, pH 7.6, 10 mM NH 4 Cl, 10 mM Mg acetate and 6 mM β-mercaptoethanol at 55 °C for 6 min. The complex was further incubated at room temperature for 10-15 min in the presence of 50 µM Onc112. Crystals were grown in sitting-drop trays in which 3 µl of ribosome complex was mixed with 3. Data collection, model building and structure refinement. All data collection was carried out at 100 °K. X-ray diffraction data were collected at beamline 24ID-C at the Advanced Photon Source at Argonne National Laboratory, with 0.3° oscillations. We used the XDS package 29 to integrate and scale collected data. All crystals belong to the orthorhombic P2 1 2 1 2 1 space group and exhibit similar cell dimensions, as previously reported for the wild-type T. thermophilus 70S crystals ( Table 1) .
We used PHASER from the CCP4 suite 30 to determine the initial solution for the structure by molecular replacement. The search model was generated from the previously published structure of the T. thermophilus 70S ribosome (PDB 1VY4) 17 with all its ligands removed. The refinement with two 70S ribosomes in the asymmetric unit was performed by rigid-body refinement, and then by five cycles of position and B-factor refinement with PHENIX 31 . After initial refinement, unambiguous difference electron density for Onc112, mRNA and P-site tRNA fMet became clearly visible in the F o -F c difference Fourier map. The Onc112 peptide, mRNA and the tRNA fMet in the P site were built into the F o -F c electron density map with Coot 32 , and the model was further refined with PHENIX 31 . The electron density for Onc112 allowed us to unambiguously build the first 13 residues. The electron density for the last six residues was not seen, thus indicating their conformational flexibility. The absence of electron density for the fMet moiety of the tRNA fMet is probably due to the hydrolysis of the aminoacyl group from the tRNA or its flexibility. The final statistics of refinement are provided in Table 1 . 
